Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hannah Bargh-Dawson
Institution:
Institute of Cancer Research
Observed institutions:
AstraZeneca (United Kingdom),
Institute of Cancer Research
ORCID:
0000-0002-8657-9484
Observed ORCID:
0000-0002-8657-9484
OpenAlex ID:
A5086815608
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
2022
·
Zena Wilson
, Rajesh Odedra
, et al.
·
Cancer Research
·
188
PDF
Radiotherapeutic enhancement using ultrasound-stimulated microbubbles: a critical review
2025
·
Hannah Bargh-Dawson
, Carol Box
, et al.
·
International Journal of Radiation Biology
·
3
Data from ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
2023
·
Zena Wilson
, Rajesh Odedra
, et al.
·
1
288 Enhancing Radioresponse using Ultrasound-Stimulated Microbubbles in Murine Head and Neck Cancer
2024
·
Hannah Bargh-Dawson
, Carol Box
, et al.
·
Radiotherapy and Oncology
Supplementary Data from ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
2023
·
Zena Wilson
, Rajesh Odedra
, et al.
Supplementary Data from ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
2023
·
Zena Wilson
, Rajesh Odedra
, et al.
Data from ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
2023
·
Zena Wilson
, Rajesh Odedra
, et al.
Show more works
View as search
Works count:
7
Citation count:
192
H-index:
2
I10-index:
1
Year
Topic
Type